Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.56 |
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.49 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8248136 | 1.00 | USP30 (0.56) | USP30KDM1AGPR119CHEK2PIK3CD | |
| SCHEMBL28059314 | 1.00 | USP30 (0.56) | USP30KDM1AGPR119CHEK2PIK3CD | |
| SCHEMBL28826952 | 0.93 | CHEK2 (0.55) | USP30KDM1AGPR119CHEK2NR1H2 | |
| SCHEMBL29796027 | 0.93 | KDM1A (0.58) | USP30KDM1AGPR119CHEK2NR1H2 | |
| SCHEMBL520668 | 0.93 | KDM1A (0.58) | USP30KDM1AGPR119CHEK2NR1H2 | |
| SCHEMBL12184833 | 0.90 | USP30 (0.52) | USP30KDM1AGPR119CHEK2NR1H2 | |
| SCHEMBL9900538 | 0.88 | GPR119 (0.57) | USP30KDM1AGPR119PIK3CDPDE4B | |
| SCHEMBL15637939 | 0.87 | USP30 (0.55) | USP30KDM1AGPR119PIK3CDPDE4B | |
| SCHEMBL9901530 | 0.87 | USP30 (0.58) | USP30KDM1AGPR119PIK3CDMEN1 | |
| SCHEMBL29577158 | 0.87 | USP30 (0.55) | USP30KDM1AGPR119PIK3CDPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2273992-B1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-05-25 | — | — | EP | disclosed |
| US-20110046110-A1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-02-24 | — | — | US | disclosed |
| US-20110046110-A1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-02-24 | — | — | US | disclosed |
| EP-2273992-A1 | QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009134973-A1 | QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009134973-A1 | QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046110-A1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | USP30 1179/4885KDM1A 1199/4885GPR119 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.